Charles River Laboratories International, Inc. (CRL)

NYSE: CRL · IEX Real-Time Price · USD
187.51
+2.68 (1.45%)
Sep 23, 2022 4:00 PM EDT - Market closed
1.45%
Market Cap 9.40B
Revenue (ttm) 3.69B
Net Income (ttm) 443.35M
Shares Out 50.14M
EPS (ttm) 8.34
PE Ratio 22.48
Forward PE 15.36
Dividend n/a
Ex-Dividend Date n/a
Volume 800,554
Open 183.31
Previous Close 184.83
Day's Range 182.02 - 188.08
52-Week Range 182.02 - 455.60
Beta 1.34
Analysts Buy
Price Target 278.12 (+48.3%)
Earnings Date Nov 1, 2022

About CRL

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provi... [Read more...]

Industry Life Sciences Tools & Services
IPO Date Jun 23, 2000
CEO James Foster
Employees 18,600
Stock Exchange NYSE
Ticker Symbol CRL
Full Company Profile

Financial Performance

In 2021, CRL's revenue was $3.54 billion, an increase of 21.08% compared to the previous year's $2.92 billion. Earnings were $390.98 million, an increase of 7.32%.

Financial Statements

Analyst Forecast

According to 20 analysts, the average rating for CRL stock is "Buy." The 12-month stock price forecast is 278.12, which is an increase of 48.32% from the latest price.

Price Target
$278.12
(48.32% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Charles River (CRL) Gains From Growing Demand Amid Macro Woes

Charles River (CRL) continues to expect that the growth rate will approach 20% in the second half of 2022.

3 days ago - Zacks Investment Research

Charles River (CRL) to Support Cure AP-4's Clinical Trials

Charles River's (CRL) manufacturing collaboration with Cure AP-4 will support the latter's Phase I/II gene therapy trials for a rare neurodegenerative disorder.

1 week ago - Zacks Investment Research

Charles River Laboratories to Present at Baird and Morgan Stanley Conferences

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories to Present at September Conferences

2 weeks ago - Business Wire

Charles River and Cure AP-4 Announce Gene Therapy Manufacturing Collaboration

ALDERLEY PARK, England--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Cure AP-4 announce a manufacturing collaboration to provide HQ plasmid DNA for Phase I/II gene therapy trials against AP-4 ...

2 weeks ago - Business Wire

Why Is Charles River (CRL) Down 10.7% Since Last Earnings Report?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock?

3 weeks ago - Zacks Investment Research

Charles River Laboratories Expands Contract Vivarium Space on West Coast

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces the addition of five CRADL locations, expanding operations to 27 vivarium facilities in key biohubs.

1 month ago - Business Wire

Charles River (CRL) Business Hurt by Macro and FX Headwinds

In Q2, the impact of foreign currency translation reduces Charles River's (CRL) reported revenue growth by 3.4%.

1 month ago - Zacks Investment Research

Charles River Laboratories is First CDMO in North America to Receive EMA Approval to Commercially Produce an Allogene...

MEMPHIS, Tenn.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River is first CDMO in North America to receive EMA approval to commercially produce an allogeneic cell therapy drug product

1 month ago - Business Wire

10 Growth Stocks Analysts Say You'll Be Glad You Bought

Keeping a list of S&P 500 growth stocks you'd like to own is a good idea. And it might pay off sooner than you think.

1 month ago - Investors Business Daily

Charles River (CRL) Q2 Earnings Top Estimates, 2022 View Cut

Revenue decline in the CDMO business drag Charles River's (CRL) Manufacturing Solutions revenues down.

1 month ago - Zacks Investment Research

Charles River Laboratories (CRL) Beats Q2 Earnings Estimates

Charles River (CRL) delivered earnings and revenue surprises of 1.09% and 2.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Charles River Laboratories Announces Second-Quarter 2022 Results

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories Announces Second-Quarter 2022 Results

1 month ago - Business Wire

Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Charles River (CRL) to Report Q2 Earnings: What's in Store?

The broad-based demand and meaningful price increases in the RMS business, particularly in North America and China, are expected to have contributed to Charles River's (CRL) Q2 top line.

1 month ago - Zacks Investment Research

These 2 Stocks May Be Recession-Proof

While many companies worry about the global economy, Charles River and Thermo Fisher are optimistic.

Other symbols: TMO
2 months ago - The Motley Fool

Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference Call

2 months ago - Business Wire

Here's Why Investors Should Retain Charles River (CRL) Now

Investors are optimistic about Charles River's (CRL) strong segmental growth and notable collaborations.

2 months ago - Zacks Investment Research

Charles River (CRL) Signs saRNA-Based Vaccine Manufacture Deal

Charles River's (CRL) industry knowledge in plasmid DNA production will benefit Ziphius Vaccines' early-stage saRNA manufacturing program.

2 months ago - Zacks Investment Research

Charles River Laboratories Announces Opening of U.K. Manufacturing Facility

WILMINGTON, Mass. & MACCLESFIELD, England--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces the opening of their High Quality Plasmid DNA Centre of Excellence at Bruntwood SciTech's Alderley...

2 months ago - Business Wire

Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine

WILMINGTON, Mass. & GHENT, Belgium--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Ziphius Vaccines collaborate to deliver early-stage clinical supply of plasmid DNA for saRNA-based vaccine prog...

3 months ago - Business Wire

Charles River (CRL) Prospers Internationally Amid FX Headwind

Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.

3 months ago - Zacks Investment Research

Charles River (CRL) to Create New Gene Therapy for Hemophilia A

Charles River (CRL) will work with ASC Therapeutics to manufacture a second-generation gene therapy for hemophilia A.

3 months ago - Zacks Investment Research

Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene Therapy for Hemophilia A

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and ASC Therapeutics announce expanded relationship to scale manufacturing for a second generation gene therapy for hemophilia A.

3 months ago - Business Wire

Charles River Labs stock slides 6% premarket after company issues profit warning for Q2

Charles River Laboratories International Inc. shares CRL, +0.89% slid 6% in premarket trade Wednesday, after the drug company issued a profit warning for the second quarter. The company is now expected ...

3 months ago - Market Watch

Charles River Laboratories to Participate in Jefferies and William Blair Conferences

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #conference--Charles River Laboratories to present at June conferences

3 months ago - Business Wire